COVID-19 Associated With Psoriasis

COVID-19 Clinical Trial

Official title:

Retrospective Clinical Study of COVID-19 Associated With the Condition and Treatment of Patients With Chinese Psoriasis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05961605
• Other study ID #: XJPF202303-PSO&COVID-19
• Status: Recruiting
• Start date: March 15, 2023
• Est. completion date: July 30, 2023

Study information

• Verified date: July 2023
• Source: Xijing Hospital
• Contact: GANG WANG, M.D.
• Phone: 13571991903
• Email: xjwgang[@]fmmu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A retrospective analysis based on database was conducted to evaluate the correlation between covid-19 infection and the condition and treatment of psoriasis patients.

Description:

Based on the patients registered in the psoriasis patient database of each center, the patients were followed up by telephone, and the severity of covid-19 infection, the change of psoriasis condition and the adjustment of treatment methods of psoriasis patients were collected for retrospective analysis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2500
• Est. completion date: July 30, 2023
• Est. primary completion date: May 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion criteria ----

1. No age limit, both male and female are accepted;

2. Psoriasis patients registered in the database;

3. Patients or their families can cooperate to complete the follow-up information survey (questionnaire, telephone, etc.) independently, and ensure the authenticity of the data provided.

Exclusion criteria ----

Patients are thought having conditions which are not appropriated for attending this clinical trial.

Related Conditions & MeSH terms

• COVID-19
• Psoriasis

Locations

Country	Name	City	State
China	The Second Hospital of Jilin University	Changchun	Jilin
China	West China Hospital, Sichuan University	Chengdu	Sichuan
China	The First Affiliated Hospital of Chongqing Medical University	Chongqing	Chongqing
China	Dalian Dermatosis Hospital	Dalian	Liaoning
China	Dermatology Hospital of Southern Medical University	Guangzhou	Guangdong
China	The First Hospital of Lanzhou University	Lanzhou	Gansu
China	Shanghai Skin Disease Hospital, Tongji University School of Medicine	Shanghai	Shanghai
China	The University of Hong Kong-Shenzhen Hospital	Shenzhen	Shenzhen
China	Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital	Tianjin	Tianjin
China	People's Hospital of Xinjiang Uygur Autonomous Region,Xinjiang Key Laboratory of Dermatology Research	Ürümqi	Xinjiang
China	Xijing Hospital, The Fourth Military Medical University	Xi'an	Shaanxi
China	Xining First People's Hospital	Xining	Qinghai

Sponsors (1)

Lead Sponsor	Collaborator
Gang Wang, MD

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The recurrence/exacerbation of psoriasis following SARS-CoV-2 infection	The impact of SARS-CoV-2 infection on psoriasis in patients receiving different baseline therapies of psoriasis.	March 15,2023 to May 30,2023
Secondary	Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection	Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection	March 15,2023 to May 30,2023